PHRX — Pharmadrug Balance Sheet
0.000.00%
Last trade - 00:00- CA$1.62m
- CA$3.23m
- 28
- 36
- 34
- 22
Annual balance sheet for Pharmadrug, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS/A | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 4.4 | 1.3 | 0.329 | 0.423 | 0.075 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0.184 | 0.058 | 0.997 | 0.019 | 0.023 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 4.69 | 1.59 | 1.34 | 0.596 | 0.147 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.122 | 0.1 | 0 | — | — |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Total Assets | 13.7 | 19.5 | 12.1 | 1.2 | 0.712 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 0.619 | 0.48 | 2.2 | 2.66 | 1.96 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.03 | 2.66 | 3.28 | 2.9 | 2.12 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| ESOP Debt Guarantee | |||||
| Other Equity | |||||
| Total Equity | 9.66 | 16.9 | 8.84 | -1.7 | -1.4 |
| Total Liabilities & Shareholders' Equity | 13.7 | 19.5 | 12.1 | 1.2 | 0.712 |
| Total Common Shares Outstanding |